KBC Group’s Collegium Pharmaceutical COLL Stock Holding History

KBC Group’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-658	Closed	-$22K	–	1851
2026 Q1	$22K	Buy	+658	New	+$27.9K	﹤0.01%	1835
2025 Q2	–	Sell	-2,336	Closed	-$70K	–	1735
2025 Q1	$70K	Hold	2,336	–	–	﹤0.01%	1674
2024 Q4	$67K	Buy	2,336 +982	+73%	+$32.5K	﹤0.01%	1752
2024 Q3	$52K	Hold	1,354	–	–	﹤0.01%	1690
2024 Q2	$44K	Hold	1,354	–	–	﹤0.01%	1687
2024 Q1	$53K	Hold	1,354	–	–	﹤0.01%	1519
2023 Q4	$42K	Sell	1,354 -285	-17%	-$7.14K	﹤0.01%	1644
2023 Q3	$37K	Sell	1,639 -1,102	-40%	-$25.1K	﹤0.01%	1665
2023 Q2	$59K	Hold	2,741	–	–	﹤0.01%	1325
2023 Q1	$66K	Sell	2,741 -614	-18%	-$16.3K	﹤0.01%	1324
2022 Q4	$78K	Hold	3,355	–	–	﹤0.01%	1283
2022 Q3	$54K	Hold	3,355	–	–	﹤0.01%	1373
2022 Q2	$59K	Sell	3,355 -15,366	-82%	-$258K	﹤0.01%	1387
2022 Q1	$381K	Hold	18,721	–	–	﹤0.01%	877
2021 Q4	$350K	Buy	18,721 +9,944	+113%	+$194K	﹤0.01%	951
2021 Q3	$173K	Buy	+8,777	New	+$190K	﹤0.01%	1091

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

KBC Group's COLL Position: Q2 2026 in Review

KBC Group sold out of Collegium Pharmaceutical (COLL) in Q2 2026, closing a stake of 658 shares — an estimated $22K sold.

KBC Group first reported a position in COLL in Q3 2021 and held it in 16 quarters. The position peaked at $381K in Q1 2022. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

KBC Group reported no remaining Collegium Pharmaceutical position as of Q2 2026 after selling out during the quarter.
KBC Group sold 658 Collegium Pharmaceutical shares in Q2 2026, an estimated $22K.
KBC Group first reported a position in Collegium Pharmaceutical in Q3 2021 and held it in 16 quarters.
KBC Group's Collegium Pharmaceutical position peaked at $381K in Q1 2022.
280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.